Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Details Narrative)

v3.24.1
Intangible Assets (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Recognition of deferred tax liability
Amortization of Intangible Assets 788,495
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) $ 7,268,143
License Rights [Member] | CoNCERT Pharmaceuticals, Inc [Member]    
Finite-Lived Intangible Assets [Line Items]    
Purchase price 8,000,000.0  
Transaction cost 1,782  
Recognition of deferred tax liability 3,037,147  
Intangible asset, tax basis $ 1,782